SLSSELLAS Life Sciences Group, Inc.

HealthcareUSD
$13.73

The financials

SELLAS Life Sciences Group, Inc. by the numbers

SELLAS Life Sciences Group, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$11M−$6.9Mn/a
Net income−$9.6M−$6.6Mn/a
Diluted EPS−$0.05−$0.07n/a

Biotechnology

Ranks #19 of 145 by Smart Score

Compare peers
ZLAB+0.82%
Zai Lab Limited
NKTR-4.3%
Nektar Therapeutics
GENB+1.2%
Generate Biomedicines, Inc.
ABCL+10%
AbCellera Biologics Inc.
NUVB-10%
Nuvation Bio Inc.
ADMA+0.23%
ADMA Biologics, Inc.